<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002816</url>
  </required_header>
  <id_info>
    <org_study_id>1951</org_study_id>
    <secondary_id>CCG-1951</secondary_id>
    <secondary_id>CDR0000064968</secondary_id>
    <nct_id>NCT00002816</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia</brief_title>
  <official_title>EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die.

      PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating
      children who have relapsed acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Improve the outcome in children with first isolated central nervous system
      (CNS), testicular, or ocular relapse of acute lymphoblastic lymphoma (ALL), and increase the
      knowledge of the characteristics of extramedullary and subsequent relapses of ALL. II.
      Quantitate, by current molecular biologic techniques, occult systemic leukemia in cases of
      conventional isolated extramedullary relapse, and examine the relationship between this
      assessment and subsequent clinical outcome, particularly overt marrow relapse. III.
      Quantitate occult systemic leukemia in subsets of extramedullary relapse that include site
      (CNS, testis, or eye), time of relapse (early or late), initial risk group, immunophenotype,
      DNA index and karyotype, gender (for CNS and eye), and ethnicity, and assess the response to
      therapy in patients entered on companion protocol CCG-B958. IV. Compare the relative
      sensitivities of two quantitative in vitro assays for occult systemic leukemia
      (fluorescence-activated cell sorter/leukemic progenitor cell clonogenic assay vs. polymerase
      chain reaction-based clonospecific assay), correlate the assays with clinical outcome, and
      assess other biologic studies of leukemic cells (e.g., neurotropic potential in the SCID
      mouse xenograft model and methotrexate sensitivity). V. Determine the event-free survival
      (EFS) and pattern of failure in children with first isolated CNS, testicular, or ocular
      relapse after treatment that includes intensive systemic chemotherapy. VI. Correlate EFS in
      patients with CNS and ocular relapse with sex, and in patients with relapse at all three
      sites with ethnicity. VII. Evaluate the impact of combined chemotherapy and radiotherapy on
      health status in survivors at two and four years after extramedullary relapse and study
      entry.

      OUTLINE: All patients receive induction chemotherapy over 5 weeks with: etoposide,
      ifosfamide/mesna, dexamethasone, vincristine, and pegaspargase (if pegaspargase is not
      available, E. coli asparaginase may be substituted throughout study); then dexamethasone,
      vincristine, pegaspargase (or E. coli asparaginase), and high-dose methotrexate with
      leucovorin rescue; and triple intrathecal chemotherapy (TIT). Following induction
      chemotherapy, all patients receive two 6-week courses of intensification therapy with
      intermittent TIT; each course consists of dexamethasone, vincristine, high-dose
      methotrexate/leucovorin, thioguanine, cytarabine, etoposide, and pegaspargase (or E. coli
      asparaginase) followed by dexamethasone, vincristine, high-dose methotrexate/leucovorin,
      thioguanine, ifosfamide/mesna, and idarubicin. Patients receive 2 additional courses of
      intensification chemotherapy followed by four 12-week courses of maintenance chemotherapy
      with vincristine and methotrexate every 2 weeks and daily oral thioguanine. Total duration of
      therapy is 78 weeks. Patients with isolated ocular relapse receive local radiotherapy prior
      to initiation of induction chemotherapy; those who also have CNS leukemia begin TIT with the
      radiotherapy. Patients with CNS relapse receive craniospinal irradiation during the first
      month of maintenance therapy, with the dose and fields based on whether they will receive TBI
      and whether they have had CNS irradiation previously. Patients with testicular relapse
      receive bilateral testicular irradiation during the first 3 weeks of intensification therapy.
      Patients are followed every 3 months for 3 years, every 6 months for 3 years, and yearly
      thereafter, or upon relapse, second malignancy, loss to follow up, or death. All patients
      undergo quality-of-life assessment at entry and 2 and 4 years after entry.

      PROJECTED ACCRUAL: Approximately 120 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <description>The evaluation of the relationship between prognostic or treatment factors and EFS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>NSC-63878</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>NSC- 34521</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>VePesid</other_name>
    <other_name>NSC-14154p</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>Idamycin</other_name>
    <other_name>NSC-256439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>Ifex</other_name>
    <other_name>NSC-109724</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>Mesnex</other_name>
    <other_name>NSC-113891</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>PEG Asparaginase</other_name>
    <other_name>PEG-ASP</other_name>
    <other_name>K/H</other_name>
    <other_name>KYOWA</other_name>
    <other_name>HAKKO</other_name>
    <other_name>NSC-644954</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>Oncovin</other_name>
    <other_name>NSC-675574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET cobalt-60 gamma ray therapy</intervention_name>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET electron therapy</intervention_name>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>EARLY # CNS RELAPSE with BM DONOR</arm_group_label>
    <arm_group_label>LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>NSC-740</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute lymphoblastic leukemia (ALL) with isolated extramedullary
        relapse Relapse occurred during or following front-line therapy for ALL Initial diagnosis
        of more than 25% blasts of L1 or L2 morphology No leukemic marrow (M1) by conventional
        assessment Patients with B precursor ALL must also be enrolled on study CCG-B958 Relapse
        occurred in the CNS, testis, or eye Ocular relapse confirmed by an ophthalmologist and by
        cytology or iris biopsy Combined CNS and ocular relapse eligible Down Syndrome patients not
        eligible No prior bone marrow transplantation in first remission No prior toxicity from any
        study drugs Patient age: Under 21

        PATIENT CHARACTERISTICS: See General Eligibility Criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L.N. Willoughby, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital for Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Grace Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Willoughby M. Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. Leuk Lymphoma. 2001 Jan;40(3-4):279-85.</citation>
    <PMID>11426549</PMID>
  </results_reference>
  <results_reference>
    <citation>Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Lazarus KH, Willoughby M. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse. Clin Cancer Res. 1999 Sep;5(9):2415-20.</citation>
    <PMID>10499612</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2004</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

